Nucleic Acid Isar Valley starts Work
CNATM is an innovation network of science and industry, which is funded with five million euros annually by the federal government, the Free State of Bavaria and participating companies.
The research network consists of scientists from LMU Munich, TUM, the universities of Regensburg and Würzburg, Helmholtz Zentrum München and 17 companies from the region around Munich.
A total of 22 applications were successfully funded, marking the start of the Nucleic Acid Isar Valley.
The CNATM's multilateral collaborations are creating a network from which novel nucleic acid-based drugs and next-generation vaccines will be developed.
Recent discoveries give hope that the ability to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many people.
There is no substance class that is better suited to personalized medicine than nucleic acids. The Cluster4Future wants to help nucleic acid therapies achieve a breakthrough and thus make a contribution that makes sense: curing people and creating jobs in and around Munich.
Prof. Dr. Thomas Carell
CNATM LMU Sprecher
Lehrstuhl für Organische Chemie I
Institut für Chemische Epigenetik (ICE-M)
Phone: 0049 (0)89 2180-77750
Prof. Dr. Dr. Stefan Engelhardt
CNATM TUM Sprecher
Institut für Pharmakologie und Toxikologie
Technische Universität München
Phone: 0049 (0)89 4140-3260
Dr. Oliver Baron
Fakultät Chemie und Pharmazie
Phone: 0049 (0)89 2180-77661